ArticleVaccines2022

The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation.

Marika Watanabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.